| Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study CM Rudin, MC Pietanza, TM Bauer, N Ready, D Morgensztern, ... The Lancet Oncology 18 (1), 42-51, 2017 | 499 | 2017 |
| Nitric oxide is consumed, rather than conserved, by reaction with oxyhemoglobin under physiological conditions MS Joshi, TB Ferguson Jr, TH Han, DR Hyduke, JC Liao, T Rassaf, ... Proceedings of the National Academy of Sciences 99 (16), 10341-10346, 2002 | 266 | 2002 |
| A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies MA Fanale, A Forero-Torres, JD Rosenblatt, RH Advani, AR Franklin, ... Clinical Cancer Research 18 (1), 248-255, 2012 | 255 | 2012 |
| Modulation of nitric oxide bioavailability by erythrocytes KT Huang, TH Han, DR Hyduke, MW Vaughn, H Van Herle, TW Hein, ... Proceedings of the National Academy of Sciences 98 (20), 11771-11776, 2001 | 231 | 2001 |
| Dynamic cell and microparticle control via optoelectronic tweezers AT Ohta, PY Chiou, TH Han, JC Liao, U Bhardwaj, ERB McCabe, F Yu, ... Journal of Microelectromechanical Systems 16 (3), 491-499, 2007 | 198 | 2007 |
| Nitric oxide reaction with red blood cells and hemoglobin under heterogeneous conditions TH Han, DR Hyduke, MW Vaughn, JM Fukuto, JC Liao Proceedings of the National Academy of Sciences 99 (11), 7763-7768, 2002 | 137 | 2002 |
| Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects KC Lasseter, J Gambale, B Jin, A Bergman, M Constanzer, J Dru, TH Han, ... The Journal of Clinical Pharmacology 47 (7), 834-840, 2007 | 127 | 2007 |
| Potent and selective agonism of the melanocortin receptor 4 with MK‐0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy R Krishna, B Gumbiner, C Stevens, B Musser, M Mallick, S Suryawanshi, ... Clinical Pharmacology & Therapeutics 86 (6), 659-666, 2009 | 95 | 2009 |
| Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates TH Han, B Zhao Drug Metabolism and Disposition 42 (11), 1914-1920, 2014 | 89 | 2014 |
| Antioxidant actions of nitroxyl (HNO) BE Lopez, M Shinyashiki, TH Han, JM Fukuto Free Radical Biology and Medicine 42 (4), 482-491, 2007 | 83 | 2007 |
| Regulation of nitric oxide consumption by hypoxic red blood cells TH Han, E Qamirani, AG Nelson, DR Hyduke, G Chaudhuri, L Kuo, ... Proceedings of the National Academy of Sciences 100 (21), 12504-12509, 2003 | 81 | 2003 |
| CYP3A‐mediated drug–drug interaction potential and excretion of brentuximab vedotin, an antibody− drug conjugate, in patients with CD30‐positive hematologic malignancies TH Han, AK Gopal, R Ramchandren, A Goy, R Chen, JV Matous, ... The Journal of Clinical Pharmacology 53 (8), 866-877, 2013 | 78 | 2013 |
| Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier TH Han, JC Liao Biochimica et Biophysica Acta (BBA)-General Subjects 1723 (1-3), 135-142, 2005 | 60 | 2005 |
| Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment B Zhao, R Chen, OA O'Connor, AK Gopal, R Ramchandren, A Goy, ... British Journal of Clinical Pharmacology 82 (3), 696-705, 2016 | 57 | 2016 |
| Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory … MA Rosenthal, P Davidson, F Rolland, M Campone, L Xue, TH Han, ... Asia‐Pacific Journal of Clinical Oncology 6 (1), 42-48, 2010 | 57 | 2010 |
| Kinetic feasibility of nitroxyl reduction by physiological reductants and biological implications MI Jackson, TH Han, L Serbulea, A Dutton, E Ford, KM Miranda, KN Houk, ... Free Radical Biology and Medicine 47 (8), 1130-1139, 2009 | 56 | 2009 |
| Antibody–drug conjugates as Cancer therapeutics: Past, present, and future HE Vezina, M Cotreau, TH Han, M Gupta The Journal of Clinical Pharmacology 57, S11-S25, 2017 | 44 | 2017 |
| Population pharmacokinetics of brentuximab vedotin in patients with CD30‐expressing hematologic malignancies H Li, TH Han, NN Hunder, G Jang, B Zhao The Journal of Clinical Pharmacology 57 (9), 1148-1158, 2017 | 40 | 2017 |
| Single‐and multiple‐dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene‐related peptide receptor antagonist, in adults TH Han, RL Blanchard, J Palcza, JB McCrea, T Laethem, K Willson, Y Xu, ... The Journal of Clinical Pharmacology 50 (12), 1367-1376, 2010 | 40 | 2010 |
| SCRX16-001 investigators. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label … CM Rudin, MC Pietanza, TM Bauer, N Ready, D Morgensztern, ... Lancet Oncol 18 (1), 42-51, 2017 | 34 | 2017 |
